A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Daehwa Pharmaceutical Co., Ltd.
Orano Med LLC
Bayer
Shengjing Hospital
Sunnybrook Health Sciences Centre
The Methodist Hospital Research Institute
Turku University Hospital
Institut Jean-Godinot
Pfizer
OncoTherapy Science, Inc.
Pfizer
CSPC Megalith Biopharmaceutical Co.,Ltd.
General Oncology, Inc.
DualityBio Inc.
OncoNano Medicine, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Cancer Trials Ireland
Ono Pharmaceutical Co. Ltd
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
University College, London
Esperas Pharma Inc.